Eurican DHPPi

Χώρα: Ηνωμένο Βασίλειο

Γλώσσα: Αγγλικά

Πηγή: VMD (Veterinary Medicines Directorate)

Δραστική ουσία:

Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus

Διαθέσιμο από:

Boehringer Ingelheim Animal Health UK Ltd

Φαρμακολογική κατηγορία (ATC):

QI07AD04

INN (Διεθνής Όνομα):

Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus

Φαρμακοτεχνική μορφή:

Lyophilisate for suspension for injection

Τρόπος διάθεσης:

POM-V - Prescription Only Medicine – Veterinarian

Θεραπευτική ομάδα:

Dogs

Θεραπευτική περιοχή:

Live Viral Vaccine

Καθεστώς αδειοδότησης:

Authorized

Ημερομηνία της άδειας:

1997-06-19

Αρχείο Π.Χ.Π.

Revised: May 2020
AN: 01998/2019
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Eurican DHPPi lyophilisate for suspension for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One dose of lyophilisate contains:
Attenuated Canine Distemper virus,
MINIMUM
MAXIMUM
STRAIN BA5
10
4.0
CCID50*
10
6.0
CCID50*
Attenuated Canine Adenovirus type 2,
STRAIN DK13
10
2.5
CCID50*
10
6.3
CCID50*
Attenuated Canine Parvovirus type 2,
STRAIN CAG2
10
4.9
CCID50*
10
7.1
CCID50*
Attenuated Canine Parainfluenza virus type 2,
Strain CGF 2004/75
10
4.7
CCID50*
10
7.1
CCID50*
(* CCID50: 50% CELL CULTURE INFECTIVE DOSE)
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Beige to pale yellow lyophilisate for suspension for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of dogs to:
-
prevent mortality and clinical signs caused by canine distemper virus
(CDV),
-
prevent mortality and clinical signs caused by infectious canine
hepatitis
virus (CAV),
-
reduce viral excretion during respiratory disease caused by canine
Revised: May 2020
AN: 01998/2019
Page 2 of 6
adenovirus type 2 (CAV-2),
-
prevent mortality, clinical signs and viral excretion caused by canine
parvovirus (CPV)*,
-
reduce viral excretion caused by canine parainfluenza virus type 2
(CPiV),
Onset of immunity: 2 weeks for all strains
Duration of immunity: at least one year after the second injection of
the primary
vaccination course for all strains.
Current available challenge and serological data show that protection
for
distemper virus, adenovirus and parvovirus* lasts for 2 years after
primary
vaccination course followed by a first annual booster.
Any decision to adapt the vaccination schedule of this veterinary
medicinal
product needs to be made on a case by case basis, taking into account
the
vaccination history of the dog and the epidemiological context.
*Protection has been demonstrated against canine parvovirus type 2a,